Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

A variant in the IL-7 gene may predict which patients with kidney cancer are more likely to experience side effects from immunotherapy.

As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding ...

today announced that a poster was presented over the weekend at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference took place at the George R. Brown Convention ...

Morningstar brands and products Company Portfolio ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

announced today that its abstract on the KVA12123 clinical program has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting to be held ...

immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer’s 39th ...

Here the authors review CAR T cell engineering and immunotherapy for cancer and juxtapose state-of-the-art developments with CAR NK cells as part of our Cancer Immunology series of Reviews.

today announced virtual poster presentations for the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting November 9-14, 2020. The presentations will update progress in two IND-ready ...